ADALA Trial: DOACs Match DAPT in Thrombosis Prevention but Cut Bleeding Risk
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-10-28 03:00 GMT | Update On 2025-10-28 03:00 GMT
Advertisement
USA: The final results of the ANDES (Antithrombotic Therapy for the Prevention of Device-Related Thrombosis After Left Atrial Appendage Occlusion) trial, presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference, have offered important insights into post-procedural therapy after Left Atrial Appendage Occlusion (LAAO).
The findings suggest that Direct Oral Anticoagulants (DOACs)
LAAO is often performed in patients with non-valvular atrial fibrillation who are at high risk of stroke but unsuitable for long-term anticoagulation. Following device implantation, there remains a potential for thrombosis formation on the device surface. Traditionally, physicians have prescribed aspirin and clopidogrel for one to three months after the procedure. However, this standard dual antiplatelet therapy carries a bleeding risk, particularly in older adults and patients with multiple comorbidities. The ANDES trial aimed to determine whether a DOAC-based approach could provide equivalent protection against thrombosis with better safety.
The trial was a multicenter, randomized, controlled study enrolling patients who had undergone successful LAAO. Participants were randomly assigned to receive either a DOAC or a DAPT regimen immediately after the procedure. The primary efficacy measure was the incidence of device-related thrombosis at 60 days, while major and clinically relevant non-major bleeding events were the main safety endpoints. Most patients enrolled were elderly, had high CHA₂DS₂-VASc scores, and were considered at high risk for both thromboembolic and bleeding events.
Findings from the trial were as follows:
- After 60 days, there was no significant difference in device-related thrombosis rates between the DOAC and DAPT groups.
- Overall event rates were low and aligned with previous registry data.
- Patients on DOACs experienced fewer bleeding complications, including gastrointestinal and access-site bleeding.
- The DOAC group showed a lower rate of net adverse clinical events.
- Short-term safety outcomes were better in patients treated with DOACs.
According to the study’s principal investigator, while DOACs did not reduce thrombosis rates compared to DAPT, they clearly offered a superior safety profile. The results indicate that a short course of DOAC therapy could serve as a safer alternative to DAPT following LAAO, especially for patients at high risk of bleeding.
The findings also highlight that factors beyond systemic anticoagulation—such as device design, incomplete endothelialization, or peri-device leaks—may play a greater role in thrombosis formation. Despite similar efficacy, the safety advantage of DOACs makes them a practical option for post-LAAO care.
Researchers emphasized that larger and longer-duration studies are needed to confirm whether the short-term safety benefits of DOACs translate into improved long-term outcomes, including stroke prevention and late device-related thrombosis. Until then, the ANDES trial contributes valuable evidence supporting personalized post-LAAO antithrombotic strategies that balance efficacy with safety in patients with atrial fibrillation.
Reference:
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.